Michael Johnson of Johnson Becker in Minneapolis has been named lead counsel for coordinating depositions for plaintiffs alleging that they developed pancreatic cancer as a result of taking one of four incretin-based drugs.
On the defense side, Richard Goetz of O’Melveny & Myers was named lead counsel for coordinating depositions for Amylin Pharmaceuticals LLC; Nina Gussack of Pepper Hamilton lead counsel for Eli Lily & Co.; Doug Marvin of Williams & Connolly for Merck Sharp & Dohme Corp.; and Loren Brown of DLA Piper for Novo Nordisk Inc.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
